NSE filing, NSE: BEACON. Summary written from the filing by ALFA Finder's alert engine.
Beacon Trusteeship Ltd: key numbers
- Share price
- ₹84.00
- Market cap
- ₹152.0 Cr
- Revenue (annual)
- ₹34.16 Cr
- Net profit (annual)
- ₹6.98 Cr
- P/E (TTM)
- 21.8×Sector 45.2×
- Promoter holding
- 46.08%
- FII holding
- 2.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beacon Trusteeship Ltd
All →Beacon Trusteeship Employee Stock Options
Beacon Trusteeship Limited has granted 50,500 Employee Stock Options to eligible employees under the BTL ESOP Plan 2025.
Beacon Trusteeship Other Announcement
Beacon Trusteeship Limited informed the exchange that Corporate Governance provisions are not applicable to the company for the quarter ended September 30, 2026.
Beacon Trusteeship Employee Stock Options
Beacon Trusteeship Limited has allotted 28,000 equity shares under its ESOP Plan 2025. This allotment increases the company's total issued and subscribed share capital to 1,80,92,913 shares.
- Value
- ₹0.17 Cr
Beacon Trusteeship Other Announcement
Beacon Trusteeship Limited's board approved amending its Memorandum of Association to expand its business scope. This enables potential future entry into new financial services segments.
Beacon Trusteeship Merger & Restructuring Worth ₹0.25 Cr
Beacon Trusteeship Limited is incorporating a Wholly Owned Subsidiary in Dubai for financial services. The investment for this expansion is approximately INR 25 Lakhs (0.25 Crore).
- Value
- ₹0.25 Cr
Beacon Trusteeship Board Meeting Outcome
Beacon Trusteeship's board approved incorporating a wholly-owned subsidiary in Dubai and altering its Memorandum of Association's object clause to diversify business activities.
- Value
- ₹0.25 Cr
Other regulatory approval announcements
All →Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.